News & Updates

Application of delgocitinib cream results in significant improvements in itch, pain, and quality of life (QoL) at week 16 in adults with moderate to severe chronic hand eczema (CHE), as shown in the pooled analysis of the phase III DELTA-1 and -2 trials.

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.